Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Ludwig Institute For Cancer Research Ltd patents


Recent patent applications related to Ludwig Institute For Cancer Research Ltd. Ludwig Institute For Cancer Research Ltd is listed as an Agent/Assignee. Note: Ludwig Institute For Cancer Research Ltd may have other listings under different names/spellings. We're not affiliated with Ludwig Institute For Cancer Research Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "L" | Ludwig Institute For Cancer Research Ltd-related inventors


Tgf-beta 3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (tgf-β3) are provided, particularly recognizing human and mouse tgf-β3, particularly antibodies and fragments that do not recognize or bind tgf-β1 or tgf-β2. Particular antibodies are provided which specifically recognize and neutralize tgf-β3. ... Ludwig Institute For Cancer Research Ltd

Plk4 inhibitors

Provided herein, inter alia, are compounds and methods for inhibiting plk4 and for treating cancer in a subject in need thereof.. . ... Ludwig Institute For Cancer Research Ltd

Methods of treating meningioma

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (egfr) and to the de2-7 egfr truncation of the egfr. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. ... Ludwig Institute For Cancer Research Ltd

Inkt cell modulators and methods of using the same

Disclosed herein are α-galactosylceramide (α-galcer) analogs and compositions thereof, methods of activating invariant natural killer t (inkt) cells using said analogs, methods of treating diseases by activating inkt cells using said analogs, and combination therapy of said analogs.. . ... Ludwig Institute For Cancer Research Ltd

Liposomal formulation of nonglycosidic ceramides and uses thereof

The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine inkt cells and induce dendritic cell (dc) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. ... Ludwig Institute For Cancer Research Ltd

Anti-metalloprotease antibody for diagnosis and treatment of cancers

Expression of proteolytically active, high molecular weight adam protease is relatively increased in tumour cells that also express the putative tumour stem cell marker cd133. An antibody or antibody fragment such as 8c7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight adam10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.. ... Ludwig Institute For Cancer Research Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ludwig Institute For Cancer Research Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ludwig Institute For Cancer Research Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###